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Calocedrus formosana (Florin) bark acetone/ethylacetate extracts are known to exert an antitumor eﬀect on some human cancer
cell lines,but themechanism isyet to be deﬁned. The aimofthisstudy wasto determine theeﬀects of Florin leaf methanolextracts
on the growth and apoptosis of human bladder cancer cell lines. MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay showed that the growth of these bladder cancer cells was potently inhibited by the Florin leaf extracts. The cell
cycle of these extract-treated cells (TCCSUP cells) was arrested at the G2/M phase as determined by ﬂow cytometry. Western blot
analysis revealed the increases of cyclin B1 and Cdc2 kinase levels, alone with the decrease of phosphorylated Cdc2 kinase, after
treating these cells with the extracts. An immunoﬂuorescence assessment of β-tubulin showed decreased levels of polymerized
tubulin in treated cells. However, the proteolytic cleavage of poly ADP-ribose polymerase and the activation of caspase-3/-8/-9
were all increased upon treatments of extracts. The concurrent increase of Bax and decrease of Bcl-2 levels indicated that the
extracts could induce apoptosis in thesetreated cells. Taken together, these results suggestthattheFlorinleafextracts maybe anef-
fective antibladder cancer agent.
1.Introduction
Accordingtoarecentstudy,urinary bladdercancerincluding
transitionalcellcarcinoma(TCC)aﬀectsmorethan2million
people worldwide [1]. Bladdercancer has been ranked as the
seventh most common type of cancer in Taiwanese males
and is still rising in incidence and prevalence [2]. Usually,
bladder cancers are grouped into two types of clinical mani-
festation, depending on the pathological stage: low-grade
(G1, G2)/noninvasive cancers (pTa, pT1) and high-grade
(G3)/muscle invasive lesions (greater than pT2) [3]. Inter-
mediate to high-grade or metastatic TCC is more diﬃcult to
treat and is lethal in ∼50% of patients [1].
Recently, many natural products have served as phar-
maceutical resources in treating and preventing human
diseases throughout the world [4, 5]. For example, over
60% of prevalent anticancer drugs, including vinblastine,
topotecan, etoposide, and paclitaxel, were originally plant-
derived compounds [6, 7]. Calocedrus formosana (Florin)
belongs to the Cupressaceae family and grows at an altitude
of 800–1500 meters in the north central mountain region
of Taiwan [8]. Extracts from the bark of Florin have been
suggested to possess some bio-active eﬀects, such as anti-
oxidative [9], anti-inﬂammatory [10], immunoregulatory
[11], antitermitic, and antifungal activities [8, 12]. It has
also been proposed to have antitumoral properties [13].
Most studies have focused on the Florin bark as a medical
source, but few studies have investigated the use of the
Florin leaf as an anticancer pharmaceutical resource. In this
study, we investigated the eﬀect of Florin leaf methanol
extracts on the growth of human bladder carcinoma cells,
including TCCSUP cells that are derived from a high-grade2 Evidence-Based Complementary and Alternative Medicine
and invasive human urinary bladder tumor [14]. Here we
demonstrate that the Florin leaf methanol extracts inhibit
growthofthesebladdercarcinoma cellsbyarresting cellcycle
at the G2/M phase and inducing apoptosis.
2.Materialsand Methods
2.1. Preparation of Florin Extracts. The Florin leaves were
collected from the Hui-SunForestStationofNationalChung
Hsing University in Taichung, Taiwan. Leaves were washed,
air-dried, and extracted twice with methanol by ultrasonica-
tion for 30 min at room temperature. The extracts were then
ﬁltered, concentrated, and then lyophilized. Florin extracts
was prepared by dissolving the lyophilized powder in dim-
ethylsulfoxide to a ﬁnal concentration of 50mg/mL. The
stock was stored at −20◦Cu n t i lu s e .
2.2. Cell Culture. H um a nbla dderca n c erc ellli n es(T CCSUP ,
T24, TSGH-8301, and RT4 cells) and SV-40-immortalized
normal uroepithelial cells (SV-HUC-1 cells) were purchased
from the Food Industry Research and DevelopmentInstitute
(FIRDI) (Hsinchu, Taiwan). TCCSUP cell line (Grade IV,
mutant p53) was isolated from an anaplastic transitional
cell carcinoma (TCC) [14]; T24 cells were derived from an
invasive bladder tumor of grade III, having p53 nonsense
mutation at codon 126 (TAC to TAG); TSGH-8301 cells
(grade II), having wt p53 but mutant Rb gene, were
derived from a well-diﬀerentiated human TCC; RT4 cells
(grade I) were established from a well-diﬀerentiated pap-
illary tumor of the bladder and have the wt p53 and Rb
gene [15]. Cell lines were cultured in McCoy’s 5A and
RPMI medium supplemented with 10% fetal bovine serum
(FBS) (Gibco, Gaithersburg, MD), L-glutamine (200mM),
and penicillin/streptomycin/amphotericin B (10,000IU/mL,
10,000μg/mL, and 25μg/mL) solution. Cells were incubated
at 37◦Cw i t h5 %C O 2.
2.3. Cell Survival Assay. Bladder cancer cells and normal
uroepithelial cells (1 × 104) were plated onto 24-well plates
and treated with Florin extracts at concentrations of 3,
6, 12, 25, and 50μg/mL or vehicle alone for 48h. MTT
(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) solution (200μL from 1mg/mL) was added to each
well, and the plates were further incubated at 37◦Cf o r4h .
Themediumwasaspiratedand theformazan productincells
was solubilized by adding DMSO. An aliquot of 150μLw a s
measured by a Microplate Autoreader (Tecan Deutschland
GmbH, Crailsheim, Germany) at wavelength of 570 nm. The
experiments were carried out in triplicate.
2.4. Apoptosis Assay-Annexin V Apoptosis and DAPI Staining.
Florin-extract treated TCCSUP cells were stained by FITC-
conjugated Annexin-V and propidium iodide (PI) using an
Annexin V-FITC Apoptosis Detection kit (BioVision, CA,
USA) and analyzed by a Becton-Dickinson FACSCalibur
with CellQuest software (BD Biosciences, San Diego, CA,
USA).After24hoftreatment,thecellswerewashedwithPBS
and ﬁxed in 2% paraformaldehyde for 30min, and then per-
meabilized with 0.1%Triton-X100inPBSfor30min. Nuclei
werestainedbyincubatingthecellswithDAPI(1μg/mL)and
examined under a ﬂuorescence microscope. Five randomly-
chosen ﬁeldsofview per well were inspected and the number
of intact nuclei and the number of multinuclear cells were
counted.
2.5. Cell Cycle Distribution by Flow Cytometry Analysis. The
treated cells were collected after trypsinization and washed
with ice-coldPBS,ﬁxedand permeabilized with70%ethanol
at −20◦C overnight. On the next day, after cells were washed
with ice-cold PBS, they were incubated with PI (20μg/mL)
and RNase (100μg/mL) for 30min at room temperature in
the dark. Data were collected from the ﬂow cytometer and
analyzed with the accompanying software (CellQuest; BD
Biosciences, San Diego, CA, USA). Ten thousand events per
sample werecountedand theexperimentswere performedin
triplicate. Datarepresent the means ± standard deviations of
3 independent experiments.
2.6. Western Blot Analysis. Cell lysates with equal amounts of
proteins, which were measured using a BCA Protein Reagent
Kit (Pierce, Rockford, IL, USA), were analyzed by Western
blot, using a rabbit polyclonal antibody to cdc2 phos-
phorylated at Tyr15 (p-Cdc2) (1:1000; R&D, Minneapolis,
MN, USA), a rabbit polyclonal cdc2 antibody (1:1000;
Cell Signaling Technology, St. Louis, MO, USA), a mouse
monoclonal antibody to cyclin B1 (sc-254; 1:200) (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), a mouse mon-
oclonal antibody to poly (ADP-ribose) polymerase (PARP)
(0.5μg/mL; from BD Biosciences, Franklin Lakes, NJ, USA),
a mouse monoclonal antibody to Bcl-2, a rabbit polyclonal
antibody to Bax (1:200; both from DAKO, Taipei, Taiwan),
an anti-β-tubulin mouse monoclonal antibody (1:20000;
Epitomics, Burlingame, California), or a mouse monoclonal
antibody against human GAPDH (1:1000; Santa Cruz, CA,
USA). Brieﬂy, samples were run on 12% sodium dode-
cylsulfate (SDS)-polyacrylamide gels and electrophoretically
transferred (SDS-PAGE) to nitrocellulose membranes (Bio-
Rad Laboratories, Hercules, CA). Nonspeciﬁc binding sites
were blockedwith 5% skim milk powder dilutedin PBS with
0.1% Tween 20 (SMP/PBST). Membranes were reacted with
primary antibody followed by incubation with horseradish
p e r o x i d a s e - l i n k e dg o a ta n t i r a b b i to rg o a ta n t i m o u s es e c -
ondary antibodies (Santa Cruz, CA, USA) which were also
diluted in PBST. Proteins were visualized by enhanced
chemiluminescence (Amersham Biosciences, San Francisco,
CA, USA). Each blot was stripped with Restore Western Blot
StrippingBuﬀer(Millipore,Billerica,MA,USA)beforebeing
reprobed with other antibodies.
2.7. Morphological Observation of Cells and Immunoﬂuo-
rescence Confocal Microscopy for Tubulin. TCCSUP cells (1
× 104) were treated by Florin extracts for 24h. The cell
morphology was observed under a reverse microscope. For
tubulin analysis, cells (1 × 104) were ﬁrst seeded onto 2-
well chamber slides (Lab-TekR; Nunc, Roskilde, Denmark)Evidence-Based Complementary and Alternative Medicine 3
and treated Florin extracts (25μg/mL) for 24h. Cells were
preﬁxed with 0.5% glutaraldehyde in 0.25% Triton X-100 in
cytoskeletonbuﬀer(CB)for60s,washedtwice(15mineach)
with CB, and reﬁxed with 1% glutaraldehyde in CB for 10
min. The slides were blocked with 2% BSA in PBST (0.1%
Tween 20 in PBS) for 2h and reacted with anti-β-tubulin
rabbitmonoclonalantibody (Abcam,Cambridge,MA,USA)
at 4◦C overnight. Slides were washed three times with PBST
and incubated with Alexa 488-conjugated antirabbit IgG
rabbit antibody (Invitrogen, Carlsbad, CA, USA) for 1h at
room temperature. Cells were counterstained with DAPI
(1μg/mL) and examined using a ZEISS LSM 510 confocal
spectral microscope.
2.8. Analysis of Soluble and Polymerized β-Tubulin. The cells
(2 × 106) were precultured for 24h and treated with
Florinextracts (25μg/mL), colchicine (0.05μg/mL), or Taxol
(0.1μg/mL) for 24h. After the cells were harvested with a
scraper and washed with PBS, the cells were added to 100μL
of microtubule-stabilizing buﬀer (MSB: 20mM Tris-HCl,
1mMMgCl 2,2mMEGTA, and 0.5%TritonX-100)contain-
ing a proteinase inhibitor cocktail (Roche, Indianapolis, IN,
USA). After incubation for 20min at room temperature, the
cell suspensions were centrifuged at 12,000×gf o r5m i na t
25◦C. The supernatants (soluble fraction) were transferred
to a new tube, while pellets were washed with MSB once
and mixed with 50μLo fp r o t e i nl y s i sb u ﬀer (RIPA). After
incubation at 4◦C for20 min, the supernatants (polymerized
fraction) were harvested by centrifugation at 100,000×gf o r
30minat4◦C.Solubleandpolymerized fractionsweremixed
separately with 4X NuPAGE LDS sample buﬀer (Invitrogen)
and stored until analysis. Twenty micrograms of soluble
and polymerized fractions were subjected to 10% SDS-
polyacrylamide (SDS-PAGE) gel electrophoresis. The sepa-
rated proteins on SDS-PAGE gel were electrically transferred
to a PVDF membrane (Perkin Elmer, Boston, MA, USA)
for immunoblot analysis. The membrane was incubated
with anti-β-tubulin rabbit monoclonal antibody (1:20,000;
Abcam, Cambridge,USA)4◦Covernight and then incubated
with horseradish peroxidase-labeled antirabbit secondary
antibody (1:5000, R&D, Minneapolis, MN, USA) for 1h.
The membrane was developed using the ECL plus Western
blotdetectionsystem(AmershamBiosciences,SanFrancisco,
CA, USA).
2.9. Determination of Caspase Activity. We used the colori-
metric substrates Ac-DEVD-pNA, Ac-IETD-pNA, and Ac-
LEHD-pNA (Biovision, California, USA) for caspase-3, -8,
and -9 assays, respectively, according to the manufacturer’s
protocol.Brieﬂy, aliquotsof cell lysates were prepared in lysis
buﬀer(50mM HEPES,pH 7.4,100mM NaCl,0.1% CHAPS,
1mM dithiothreitol, 0.1mM EDTA) and then incubated
with 200μM of substrate in assay buﬀer (50mM HEPES,
pH 7.4, 100mM NaCl, 0.1% CHAPS, 10mM dithiothreitol,
0.1mM EDTA, 10% glycerol) in 96-well plates at 37◦Cf o r
2h. Absorbance of the cleaved product was measured at
405nm in a TECAN Microplate Reader.
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Figure 1: Eﬀects of Florin extracts on cell viability of human blad-
der cancer cells (TCCSUP, T-24, TSGH-8301, and RT-4 cells) and
immortalized normal uroepithelial cells (SV-HUC-1 cells). These
cells were treated with various concentrations (3, 6, 12, 25, and
50 μg/mL) of Florin extracts or vehicle only for 48h. Results are
presented as mean ± S.D. (n = 3).
2.10. Statistics. All data are presented as mean ± S.D. The
diﬀerences between the treated cells and the control cells
were analyzed by Student’s t-test. A P value < .05 was
considered statistically signiﬁcant.
3.Results
3.1. Inhibition of Bladder Cancer Cell Growth by Diﬀerent
Dosages of Florin Extracts. Four bladder cancer cell lines
(including TCCSUP, T24, TSGH-8301, and RT-4 cells) and
immortalized normal uroepithelial cells (SV-HUC-1) were
treated with various concentrations (3–50μg/mL) of Florin
extracts for 48h. The growth of these cells was determined
by MTT assay. As shown in Figure 1,t r e a t m e n tw i t h
Florin extracts for 48h inhibited growth of T-24, TCCSUP
& TSGH-8301 cells, and RT-4 cells in a concentration-
dependent manner with IC50so f∼9-10 and ∼17μg/mL,
respectively. Treatment of SV-immortalized normal uroep-
ithelial cells (SV-HUC-1 cells) with Florin extracts for 48h
also exhibited concentration-dependent growth inhibition
but with a higher IC50 (∼27μg/mL). These results indicate
that Florin extracts inhibit growth of malignant bladder
cancer cells more eﬀectively than normal uroepithelial cells.
3.2. ApoptoticEﬀect of Florin Extracts on Bladder Cancer Cells.
TCCSUP cells were treated with 25μg/mL of Florin extracts
for 18 and 24h, and then stained with Annexin V-FITC
and DAPI. With Annexin V-FITC staining, early apoptosis
was clearly detectable in cells treated with 25μg/mL of
Florin extracts for 18h (11.7%) (Figure 2(A)). The apop-
totic nucleus-containing adherent and supernatant cells,
which exhibitedhighlyﬂuorescentcondensedchromatinand
cleaved nuclei, were observed in cells treated with 25μg/mL4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Analysis of the eﬀect of Florin extracts on apoptosis in TCCSUP cells. (A) Cells were treated with 0, 6, 12, or 25μg/mL of Florin
extracts. After 18h, the percentage of early apoptotic cells was assessed by Annexin-V/PI binding assay. (B) After 24h, the adherent cells or
suspensioncells were collected and subjected to DAPI staining.(C) The ratio of DAPI-stained cells was calculated and the data are presented
as mean ± S.D. ∗P<. 05, ∗∗P<. 01. (D) After the cells were treated with 0, 6, 12, and 25μg/mL of Florin extracts for 48h, the PARP protein
was resolved on 10% SDS-PAGE and then Western blot was performed. GAPDH was used as a control.
of Florin extracts (Figure 2(B), e and f). The apoptosis index
of these treated cells is shown in Figure 2(C). After 48h of
treatmentwith12μg/mLor25μg/mLofFlorinextracts,a85-
kDaproteolyticproductofPARPwas observed(Figure 2(D),
lanes 3 and 4).
3.3. Cell Cycle Arrest at the G2/M Phase. To study the eﬀect
of Florin extracts on the diﬀerent phases of cell cycles, we
mainly used TCCSUP cells for the experiments. TCCSUP
cells were treated with various concentrations (6, 12, and
25μg/mL) of Florin extracts for 24h and then analyzedEvidence-Based Complementary and Alternative Medicine 5
by a ﬂuorescence-activated cell sorter (FACS). The per-
centage of TCCSUP cells at the G2/M phase markedly
increased in a Florin-extracts concentration-dependent
manner (Figure 3(a)). The percentages of TCCSUP cells in
the G2/M phase were estimated to be 29.4 ± 0.3, 36.0
± 2.7, 59.4 ± 0.4, and 94.6 ± 1.1% after treatment of
these cells with 0, 6, 12, and 25μg/mL of Florin extracts,
respectively (Table 1). These results indicate that Florin
extracts arrest TCCSUP cells at the G2/M phase. To test
t h et i m ed e p e n d e n c eo ft h ee ﬀect, cells were treated with
25μg/mL of Florin extracts for 6, 12, 24, 36, and 48h, and
the cell cycle of treated cells were analyzed. As shown in
Figure 3(b) and Table 2,t h eG 2 / Ma r r e s tw a so b s e r v e da t
6h (59.6 ± 2.1%), reached a maximal level (>90%) (94.6
± 0.1%) at 24h, and then gradually decreased (due to cell
death). The sub-G1 cells increased to 15.4 ± 2.3% at 48h.
These results suggest that Florin extracts induce G2/M phase
arrest in a time-dependent manner.
3.4. Eﬀects of Florin Extracts on Cell Cycle-Related and Apop-
totic Proteins. The expression of cyclin B1, Cdc2, and phos-
phorylated Cdc2 (p-Cdc2), key regulators of cell entry into
mitosis, was monitored by immunoblotting assay. The treat-
ment time points are as indicated in Figure 3(b).A ss h o w n
in Figure 4(a), the levels of cyclin B1 and Cdc2 kinase were
upregulated after a 6h treatment of TCCSUP cells with
Florin extracts (lane 2). Interestingly, the slow migrating
forms of cyclin B1 and Cdc2 were converted to the fast
migrating forms of these molecules after treatment of cells
with Florin extracts for 24 and 36h (lanes 6 and 8). The slow
and fast migrating forms may represent hyperphosphory-
lated and hypophosphorylated (or dephosphorylated) forms
of cyclinB1 and Cdc2, respectively. Cdc25C was upregulated
after treatment of the cells with Florin extracts for 6, 12,
and 24h (Figure 4(a), lanes 2, 4, and 6), then decreased after
36h treatment (lane 8), as compared with untreated cells
(Figure 4(a), lanes 1, 3 and 5). On the other hand, Florin
extracts induced a decrease of P-Cdc2 in a time-dependent
manner. Because the Cdc2 level was not signiﬁcantly altered
after treatment of cells with Florin extracts for 12, 24,
and 36h, this suggests that treatment with Florin extracts
induces dephosphorylation of P-Cdc2 in a time-dependent
manner. This suggestion is supported by the observation
thatthehypophosphorylatedordephosphorylatedform(fast
migrating form) of Cdc2 was the major molecule of Cdc2 in
cells treated with Florin extracts for 24 and 48h (Figure 4(a),
lanes 6 and 8). Increase of cyclin B1 levels and Cdc2
dephosphorylation (activation) is known to be associated
with mitotic arrest [16, 17]. These results support the
suggestion that Florin extracts arrest cells at the G2/M phase
of the cell cycle. In this study, we also found that Florin-
extracts induced phosphorylation (slow migrating form)
and degradation of Bcl-2 correlated with the production of
the fast migrating form (dephosphorylated form) of Cdc-
2( Figure 4(a),l a n e s6a n d8 ) .T h e s er e s u l t sm a yi m p l y
that the increase of Cdc2 kinase activity is associated with
degradation or instability of Bcl-2, an antiapoptotic protein.
Furthermore, after TCCSUP cells were treated with 12 or
Table 1: Flow cytometry analysis in TCCSUP cells treated with
Florin extracts.
Dose
Percentage (mean ± S.D.) of TCCSUP bladder cancer
cells at each cell cycle phase after treatment with
diﬀerent concentrations of Florin extracts (μg/mL) at
24h.
subG1 (%) G1 (%) S (%) G2/M (%)
0
(control) 0.8 ± 0.3 54.6 ± 0.5 15.2 ± 0.1 29.4 ± 0.3
61 . 4 ± 0.5 46.6 ± 2.5 16.0 ± 1.7 36.0 ± 2.7∗
12 2.9 ± 0.1 24.9 ± 1.1 12.8 ± 0.8 59.4 ± 0.4∗∗
25 1.3 ± 0.2 2.2 ± 0.2 1.9 ± 1.3 94.6 ± 1.1∗∗∗
aTCCSUP cell growth was arrested at the G2/M phase after Florin-extract
treatment in a dose-dependent manner, and these cells were signiﬁcantly
diﬀerent from the control cells.
bCell numbers decreased signiﬁcantlyat the G1 phase (∗P<. 05, ∗∗P<. 01,
∗∗∗P<. 001).
25μg/mL of Florin extracts for 24h, the level of Bax,
a proapoptotic protein, increased in accompany with the de-
crease of Bcl-2 levels (Figure 4(b),l a n e s3a n d4 ) .
3.5. Florin Extracts Inhibit Tubulin Polymerization in TCC-
SUP Cells. We next wanted to determine whether the
quantitative change in tubulin levels and the altered balance
of polymerization and depolymerization account for the
eﬀectsof Florinextracts. We fractioned the soluble and poly-
merized tubulin in Florin-extract-treated cells, performed
Western blot analysis, and determined the percentage of
tubulin polymers to monomers. As shown in Figure 5(a),
treatment of cells with Florin extracts for 24h dramatically
decreased the tubulin levels (>90%) as compared to control.
Treatment with Taxol (0.1μg/mL), an inhibitor of tubulin
depolymerization, profoundly increased the polymerized
tubulin (approximately ﬁvefold as compared to control)
(Figure 5(b)). We also determined the eﬀects of Florin
extracts on the microtubule network in TCCSUP cells by
immunoﬂuorescence confocal microscopy (Figure 6). Nor-
mal prometaphase microtubule organization in the control
cells is shown in Figure 6(a). Treatment with a high concen-
tration of Florin (25μg/mL) caused a signiﬁcant reduction
of microtubule density in the apoptotic cells (Figure 6(b)).
Furthermore, treatment with colchicine (0.1μg/mL) resulted
in inhibition of microtubule polymerization and reduction
of microtubule density in the cytoplasm (Figure 6(c)).
In contrast, Taxol (0.1μg/mL) treatment resulted in the
formation of microtubule “bundles” (Figure 6(d)). In the
experiments, we also determined that the amount of β-
tubulin which represented half of the total amount of
polymerized tubulin. (data not shown).
3.6. Eﬀects of Florin Extracts on the Activities of Caspase-
3, -8, and -9 in TCCSUP Cells. Caspase-3, -8, and -9
play crucial roles in the apoptotic pathway, which con-
tain a mitochondria-related “intrinsic pathway” and death
receptor-related “extrinsic pathway” [18, 19]. To study the
eﬀect of time length on caspase-3, -8, and -9 activities,
TCCSUP cells were treated with 25μg/mL of Florin extracts
for 12, 24, and 48h. The activities of these enzymes in the6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Flow cytometry analysis of TCCSUP cells treated with Florin extracts. (a) Cells were treated with 6, 12, and 25μg/mL of Florin
extract for 24h. (b) Cells were treated with 25μg/mL of Florin extracts for 6, 12, 24, 36, and 48h and then stained with PI. Florin extracts
induced signiﬁcantcell cycle arrest at the G2/M phase; however, cell numbers decreased signiﬁcantlyat phase G1 (∗P<. 05).
treated cells were analyzed. As shown in Figure 7,c o m p a r e d
to the control treatment, caspase-8 and -3 activities were
signiﬁcantly increased after treatment of cells with Florin
extracts for 12, 24, and 48h. For example, the caspase-9
activity was increased by 1.5-fold after 24h, as compared to
the control treatment.
4.Discussion
In the current study, we have demonstrated that Florin
extracts inhibited cell proliferation (Figure 1), and arrested
t h ec e l lg r o w t ha tt h eG 2 / Mp h a s e( Figure 3). Florin extracts
appeared to have a potent selectivity toward 4 bladder
cancer cells (IC50s = ∼9–17μg/mL versus IC50 = ∼27μg/mL
in SV40-immortalized normal uroepithelial cells). Presently,
Florin extracts used is very crude; its antibladder cancer
cell activity with IC50so f9 – 1 7 μg/mL is relatively potent.
However,itispossiblethatthebloodortissueconcentrations
of Florin extracts active components may not be able to
reach the IC50s. To address this potential problem, one could
i n c r e a s et h ed o s a g eo fF l o r i ne x t r a c t st oaf e wh u n d r e d
mg/kg. However, the potential side or toxicity eﬀects ofEvidence-Based Complementary and Alternative Medicine 7
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Figure 4: Western blot analysis of cell cycle regulatory protein levels and apoptosis proteins in TCCSUP cells treated with Florin extracts.
(a) Cdc25C, Cdc-2, pCdc-2, cyclin-B1, and Bcl-2 proteins were analyzed after cells were exposed to Florin extracts. Cells were treated with
25μg/mL of Florin extracts for 6, 12, 24, and 36h. Proteins (50μg) from each sample was resolved on 12% SDS-PAGE and Western blot
was performed. GAPDH was used as a control. The thick and thin bars indicate the locations of the fast (dephosphorylated) and slow
(phosphorylated) migrating forms of cyclin B1, P-Cdc2, or Cdc2, respectively. (b) Expression of Bcl-2 and Bax proteins in TCCSUP cells
was analyzed. Cells were treated with 6, 12, and 25μg/mL of Florin extracts for 24h. Proteins (50μg) from each sample were resolved
on 12% SDS-PAGE and Western blot was performed. GAPDH was used as a control. The two slow migrating forms of Bcl2 may be the
hyperphosphorylated forms of Bcl2.
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Figure 5: Determination of the percentages of polymerized to solubleβ-tubulin in TCCSUP cells treated with Florin extracts. Cells (2
× 106) were pre-cultured for 24h and treated with Florin extracts (25μg/mL), colchicine (0.05μg/mL), or Taxol (0.1μg/mL) for 24h.
Treated cells were harvested, lyzed, and soluble and polymerized fractions of tubulin were obtained. About 25μg of solubleand polymerized
fraction proteins were used in the Western blot analysis,with antirabbit β-tubulin monoclonalantibody as a primary antibody. Images were
photographed (a), and the percentages of polymerized to soluble tubulin were calculated using the band area (b).
this high dose of Florin extracts have to be addressed. Al-
ternatively, the active components in the Florin extracts
could be further concentrated or puriﬁed by conventional
chromatographic techniques using antibladder cancer cell
activityassay.Furtherstudiesmayalsoberequiredtoidentify
the active components responsible for the observed antitu-
mor eﬀect of Florin extracts.
Upregulation of cyclin B1/Cdc2 kinase activity is known
to be involved in the G2/M phase transition of the cell cycle
[20, 21]. Cyclin B1 and Cdc2 kinase regulate the entry and
progression of the mitotic phase in eukaryotic cells. A pre-
vious report showed that the activation of Cdc2 kinase at
the G2/M transition requires accumulation of cyclin B1
and Cdc2 [17, 21]. Cdc2 kinase is activated by the speciﬁc
phosphatase Cdc25C [22, 23]. Here we demonstrate that
treatment of bladder cancer cells with Florin extracts results
in an increase of cyclin B1/Cdc2 kinase activity as evidenced
by increased levels of dephosphorylated Cdc2 kinase (acti-
vated Cdc2 kinase) in cells treated with Florin extracts. The
microtubule network plays an important role in the regula-
tion of mitotic apparatus. Cells are arrested in the M phase
when microtubule dynamics are disrupted. Our data shows
thattreatmentwithFlorinextractsinducesdepolymerization
of microtubules in bladder cancer cells. This occurs by
decreasing β-tubulin expression in these cells. Microtubules
are composed of α-tubulin and β-tubulin. Several reports
have indicated that both the microtubule-stabilizing agents
(such as Taxol) and the microtubule-depolymerizing agents
(such as Vinblastine and colchicine) [24–26] exhibit potent
anticancer activity by inhibiting cell cycle progression and8 Evidence-Based Complementary and Alternative Medicine
(a) (b)
(c) (d)
Figure 6: Eﬀect of treatment with Florin extracts on the amount of prometaphase microtubules in TCCSUP cells. (a) Cells were incubated
with vehicle (0.1% dimethylsulfoxide) for 24h. (b) Cells were treated with 25μg/mL of Florin extracts, (c) 0.1μg/mL of colchicine, or (d)
0.1μg/mL Taxol for 24h. Control indicates vehicle-treated cells. Microtubules (green) and nuclei (blue) are shown. Scale bar, 20μm. Some
of the β-tubulin are indicated by white arrows in (b), (c), and (d). (630x original magniﬁcation).
Table 2: Flow cytometry analysis in TCCSUP cells treated with
Florin extracts.
Time (h)
Percentage (mean ± S.D.) of TCCSUP bladder cancer
cells at each cell cycle phase after treatment with Florin
extract (25μg/mL) at diﬀerent time points
subG1 (%) G1 (%) S (%) G2M (%)
00 . 5 ± 0.1 55.9 ± 3.9 18.2 ± 2.8 25.4 ± 1.9
60 . 6 ± 0.4 24.3 ± 1.6 15.1 ± 3.3 59.6 ± 2.1∗∗
12 0.7 ± 0.1 2.9 ± 0.5 14.1 ± 0.5 82.3 ± 0.1∗∗∗
24 1.7 ± 0.7 1.7 ± 0.6 2.0 ± 0.2 94.6 ± 0.1∗∗∗
36 4.7 ± 2.0 3.0 ± 1.7 4.2 ± 1.6 88.1 ± 1.5∗∗∗
48 15.4 ± 2.3 3.4 ± 0.5 5.6 ± 0.4 75.6 ± 3.3∗∗∗
aTCCSUP cell growth was arrested at the G2/M phase after Florin-extracts
treatment in a time-dependent manner, and these cells were signiﬁcantly
diﬀerent from those at baseline (0).
bThere was a signiﬁcant diﬀerence between these cells and those in the
control group (∗∗P<. 01, ∗∗∗P<. 001).
inducing cell apoptosis [26, 27]. Thus, we used colchicine
and Taxol as controls. The experimental results reveal that
treatment of bladder cancer cells with Florin extracts leads
to cell cycle arrest at the G2/M phase. This appears to be
mediated, at leastin part, bydepolymerizing microtubulesas
colchicine does.
Anti-microtubule agents, including Taxol, Doxetaxel,
Vincristine, and colchicine, have been shown to induce cell
growth arrest, phosphorylation of Bcl-2, increased Bax pro-
tein levels, and ﬁnally cell death. This involves the mito-
chondrial pathway and activation of caspase-9 and caspase-
3[ 28–30]. Bcl-2 is known to play an important role in the
intrinsic apoptosis pathway and protects the microtubule
integrity [18]. Here we demonstrated that treatment with
Florin extracts induce apoptosis in bladder cancer cells, as
determined by Annexin-V assay and caspase-3, -8, and -
9 activity measurement. The apoptotic activity of Florin
extracts in bladder cancer cells appears to be mediated by
(1) increase of cyclin B1/Cdc2 kinase activity, (2) inhibition
of tubulin polymerization, (3) phosphorylation and degra-
dation of Bcl-2, an antiapoptotic protein, and (4) increased
production of Bax, an apoptotic protein.
The death receptor-signaling cascade belongs to the ex-
trinsic pathway [19] which involves activation of caspase-8.
Our study shows that TCCSUP cells treated with Florin for
12h exhibit up-regulation of both initiator caspase (caspase-
8 and -9) and eﬀector caspase (caspase-3) and that caspase-8
is upregulated earlier than caspase-9 and caspase-3 in theseEvidence-Based Complementary and Alternative Medicine 9
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Figure7:Eﬀects ofFlorinextracts oncaspase-3,-8,and-9activities
in TCCSUP cells. After treatment with 25μg/mL of Florin extracts
for 12, 24, and 48h, cell lysates were prepared and enzymatic
activities of caspase-3, -8, and -9 were measured by colorimetric
assay. The caspase-3, -8, and -9 activities in control cells were taken
as 1-fold, and the relative changes of these activities in the treated
cells were estimated (∗P<. 05, ∗∗P<. 01).
cells treated with Florin extracts. Caspase-3, which cleaves
PARP protein, plays an important role in the execution of
apoptosis. Elevated levels of caspase-3 (up to 2.5-fold of
control) are observed after 48h of Florin-extract treatment.
Therefore, our results suggest that apoptosis of Florin
extract-treatedTCCSUPcellsoccursthroughthearrestofthe
cell cycle at the G2/M phase and then proceeds through both
the death receptor and the mitochondrial pathways.
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